Viriom

Executive Summary

Viriom Inc. is a US-based biopharmaceutical company dedicated to developing affordable small-molecule therapies for infectious and malignant diseases, with a primary focus on HIV, Hepatitis, and respiratory infections. Founded in 2016 and headquartered in San Diego, Viriom leverages a global drug development platform and strategic partnerships to advance its pipeline and expand global access to innovative treatments. The company's mission centers on addressing the unmet medical needs in underserved populations by providing cost-effective alternatives to existing therapies. Although Viriom is private and does not disclose financial details, its targeted approach and collaborative model position it as a promising player in the antiviral and oncology space. The company's pipeline emphasizes known targets and repurposed compounds, aiming for accelerated development paths. With a lean operational structure, Viriom seeks to achieve clinical proof-of-concept efficiently while navigating regulatory pathways in multiple geographies.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for lead HIV candidate60% success
• Q3 2026Announcement of new partnership for Hepatitis program70% success
• TBDPreclinical data release for respiratory infection asset50% success